Hybrid inhibitors of DNA and HDACs remarkably enhance cytotoxicity in leukaemia cells

References

• Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med 2006;12:440–50.
   PubMed Web of Science ®Google Scholar
• Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer 2012;12:801–17.
   PubMed Web of Science ®Google Scholar
• Srivastava M, Raghavan SC. DNA double-strand break repair inhibitors as cancer therapeutics. Chem Biol 2015;22:17–29.
   PubMedGoogle Scholar
• Bartkova J, Hamerlik P, Stockhausen MT, et al. Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas. Oncogene 2010;29:5095–102.
   PubMed Web of Science ®Google Scholar
• Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005;434:907–13.
   PubMed Web of Science ®Google Scholar
• Dhillon KK, Swisher EM, Taniguchi T. Secondary mutations of brca1/2 and drug resistance. Cancer Sci 2011;102:663–9.
   PubMed Web of Science ®Google Scholar
• Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell 1999;4:511–8.
   PubMed Web of Science ®Google Scholar
• Moynahan ME, Pierce AJ, Jasin M. Brca2 is required for homology-directed repair of chromosomal breaks. Mol Cell 2001;7:263–72.
   PubMed Web of Science ®Google Scholar
• O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell 2015;60:547–60.
   PubMed Web of Science ®Google Scholar
• Gao CZ, Dong W, Cui ZW, et al. Synthesis, preliminarily biological evaluation and molecular docking study of new olaparib analogues as multifunctional parp-1 and cholinesterase inhibitors. J Enzyme Inhib Med Chem 2019;34:150–62.
   PubMed Web of Science ®Google Scholar
• Catovsky D, Else M, Richards S. Chlorambucil–still not bad: A reappraisal. Clin Lymphoma Myeloma Leuk 2011;11: S2–S6.
   PubMedGoogle Scholar
• Galton DA, Israels LG, Nabarro JD, Till M. Clinical trials of p-(di-2-chloroethylamino)-phenylbutyric acid (cb 1348) in malignant lymphoma. Br Med J 1955;2:1172–6.
   PubMed Web of Science ®Google Scholar
• Everett JL, Roberts JJ, Ross WCJ. Aryl-2-halogenoalkylamines. Part xii. Some carboxylic derivatives of nn-di-2-chloroethylaniline. J Chem Soc 1953;486:2386–92.
   Google Scholar
• Noll DM, Mason TM, Miller PS. Formation and repair of interstrand cross-links in DNA. Chem Rev 2006;106:277–301.
   PubMed Web of Science ®Google Scholar
• Panasci L, Paiement JP, Christodoulopoulos G, et al. Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair. Clin Cancer Res 2001;7:454–61.
   PubMed Web of Science ®Google Scholar
• Christodoulopoulos G, Malapetsa A, Schipper H, et al. Chlorambucil induction of hsrad51 in b-cell chronic lymphocytic leukemia. Clin Cancer Res 1999;5:2178–84.
   PubMed Web of Science ®Google Scholar
• Bello VE, Aloyz RS, Christodoulopoulos G, Panasci LC. Homologous recombinational repair vis-a-vis chlorambucil resistance in chronic lymphocytic leukemia. Biochem Pharmacol 2002;63:1585–8.
   PubMed Web of Science ®Google Scholar
• Kuo MH, Allis CD. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 1998;20:615–26.
   PubMed Web of Science ®Google Scholar
• Yao YL, Yang WM. Beyond histone and deacetylase: an overview of cytoplasmic histone deacetylases and their nonhistone substrates. J Biomed Biotechnol 2011;2011:(1–15.
   Google Scholar
• Lakshmaiah KC, Jacob LA, Aparna S, et al. Epigenetic therapy of cancer with histone deacetylase inhibitors. J Cancer Res Ther 2014;10:469–78.
   PubMed Web of Science ®Google Scholar
• Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38–51.
   PubMed Web of Science ®Google Scholar
• Parasar B, Chang PV. Chemical optogenetic modulation of inflammation and immunity. Chem Sci 2017;8:1450–3.
   PubMed Web of Science ®Google Scholar
• Kassab SE, Mowafy S, Alserw AM, et al. Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma. J Enzyme Inhib Med Chem 2019;34:1062–77.
   PubMed Web of Science ®Google Scholar
• Mutule I, Borovika D, Rozenberga E, et al. 5-membered cyclic hydroxamic acids as HDAC inhibitors. J Enzyme Inhib Med Chem 2015;30:216–23.
   PubMed Web of Science ®Google Scholar
• Ruzzolini J, Laurenzana A, Andreucci E, et al. A potentiated cooperation of carbonic anhydrase ix and histone deacetylase inhibitors against cancer. J Enzyme Inhib Med Chem 2020;35:391–7.
   PubMed Web of Science ®Google Scholar
• Xia J, Hu H, Xue W, et al. The discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay. J Enzyme Inhib Med Chem 2018;33:525–35.
   PubMed Web of Science ®Google Scholar
• Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, saha) for refractory cutaneous t-cell lymphoma (ctcl). Blood 2007;109:31–9.
   PubMed Web of Science ®Google Scholar
• VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH. Romidepsin (istodax, nsc 630176, fr901228, fk228, depsipeptide): A natural product recently approved for cutaneous t-cell lymphoma. J Antibiot (Tokyo) 2011;64:525–31.
   PubMed Web of Science ®Google Scholar
• Raedler LA. Farydak (panobinostat): first HDAC inhibitor approved for patients with relapsed multiple myeloma. Am Health Drug Benefits 2016;9:84–7.
   PubMedGoogle Scholar
• Lee HZ, Kwitkowski VE, Del Valle PL, et al. FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral t-cell lymphoma. Clin Cancer Res 2015;21:2666–70.
   PubMed Web of Science ®Google Scholar
• Song Y, Lim J, Seo YH. A novel class of anthraquinone-based HDAC6 inhibitors. Eur J Med Chem 2019;164:263–72.
   PubMed Web of Science ®Google Scholar
• Lim J, Song Y, Jang JH, et al. Aspirin-inspired acetyl-donating HDACs inhibitors. Arch Pharm Res 2018;41:967–76.
   PubMed Web of Science ®Google Scholar
• Cini E, Faltoni V, Petricci E, et al. Antibody drug conjugates (ADCs) charged with HDAC inhibitor for targeted epigenetic modulation. Chem Sci 2018;9:6490–6.
   PubMed Web of Science ®Google Scholar
• Yun F, Cheng C, Ullah S, et al. Thioether-based 2-aminobenzamide derivatives: novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. Eur J Med Chem 2019;176:195–207.
   PubMed Web of Science ®Google Scholar
• Cheng C, Yun F, He J, et al. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. Eur J Med Chem 2019;173:185–202.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhao S, Li H, et al. Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors. Eur J Med Chem 2019;168:110–22.
   PubMed Web of Science ®Google Scholar
• Hancock WW, Akimova T, Beier UH, et al. HDAC inhibitor therapy in autoimmunity and transplantation. Ann Rheum Dis 2012;71: i46–54.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang J, Jiang Q, et al. Zinc binding groups for histone deacetylase inhibitors. J Enzyme Inhib Med Chem 2018;33:714–21.
   PubMed Web of Science ®Google Scholar
• Shubassi G, Robert T, Vanoli F, et al. Acetylation: a novel link between double-strand break repair and autophagy. Cancer Res 2012;72:1332–5.
   PubMed Web of Science ®Google Scholar
• Xie R, Li Y, Tang P, Yuan Q. Rational design, synthesis and preliminary antitumor activity evaluation of a chlorambucil derivative with potent DNA/HDAC dual-targeting inhibitory activity. Bioorg Med Chem Lett 2017;27:4415–20.
   PubMed Web of Science ®Google Scholar
• Xie R, Tang P, Yuan Q. Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties. Medchemcomm 2018;9:344–52.
   PubMed Web of Science ®Google Scholar
• Olive PL, Banath JP. The comet assay: a method to measure DNA damage in individual cells. Nat Protoc 2006;1:23–9.
   PubMed Web of Science ®Google Scholar
• Fillingham J, Keogh MC, Krogan NJ. Gammah2ax and its role in DNA double-strand break repair. Biochem Cell Biol 2006;84:568–77.
   PubMed Web of Science ®Google Scholar
• Krogh BO, Symington LS. Recombination proteins in yeast. Annu Rev Genet 2004; 38:233–71.
   PubMed Web of Science ®Google Scholar
• Singleton MR, Wentzell LM, Liu Y, et al. Structure of the single-strand annealing domain of human rad52 protein. Proc Natl Acad Sci U S A 2002;99:13492–7.
   PubMed Web of Science ®Google Scholar
• Hubbert C, Guardiola A, Shao R, et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002;417:455–8.
   PubMed Web of Science ®Google Scholar
• Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007;1:19–25.
   PubMed Web of Science ®Google Scholar
• Karmakar S, Purkait K, Chatterjee S, Mukherjee A. Anticancer activity of a cis-dichloridoplatinum(ii) complex of a chelating nitrogen mustard: Insight into unusual guanine binding mode and low deactivation by glutathione. Dalton Trans 2016;45:3599–615.
   PubMed Web of Science ®Google Scholar
• O’Connor PM, Ferris DK, Pagano M, et al. G2 delay induced by nitrogen mustard in human cells affects cyclin a/cdk2 and cyclin b1/cdc2-kinase complexes differently. J Biol Chem 1993;268:8298–308.
   PubMed Web of Science ®Google Scholar
• Kim MJ, Kim H, Cha IJ, et al. High-throughput screening of inhibitory potential of nine cytochrome p450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2005;19:2651–8.
   PubMed Web of Science ®Google Scholar
• Shon JC, Shin HS, Seo YK, et al. Direct infusion ms-based lipid profiling reveals the pharmacological effects of compound k-reinforced ginsenosides in high-fat diet induced obese mice. J Agric Food Chem 2015;63:2919–29.
   PubMed Web of Science ®Google Scholar
• Aloyz R, Grzywacz K, Xu ZY, et al. Imatinib sensitizes cll lymphocytes to chlorambucil. Leukemia 2004;18:409–14.
   PubMed Web of Science ®Google Scholar
• Ha K, Fiskus W, Choi DS, et al. Histone deacetylase inhibitor treatment induces ‘brcaness’ and synergistic lethality with parp inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget 2014;5:5637–50.
   PubMed Web of Science ®Google Scholar